BSX Quote, Financials, Valuation and Earnings

Globus Medical, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 15.47%. Boston Scientific Corp.'s return on equity of 12.46% beat Globus Medical, Inc.'s return on equity of 10.08%.

Boston Scientific Corp. has a consensus price target of $118.78, signalling upside risk potential of 63.66%. On the other hand Globus Medical, Inc. has an analysts' consensus of $107.17 which suggests that it could grow by 23.1%. Given that Boston Scientific Corp. has higher upside potential than Globus Medical, Inc., analysts believe Boston Scientific Corp. is more attractive than Globus Medical, Inc..

Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.621%.

Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Boston Scientific Corp.'s net income of $670M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 38.94x while Globus Medical, Inc.'s PE ratio is 28.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.62x versus 4.33x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 27.89%. Boston Scientific Corp.'s return on equity of 12.46% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Boston Scientific Corp. has a consensus price target of $118.78, signalling upside risk potential of 63.66%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 27.87%. Given that Boston Scientific Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Boston Scientific Corp. is more attractive than Intuitive Surgical, Inc..

Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Boston Scientific Corp.'s net income of $670M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 38.94x while Intuitive Surgical, Inc.'s PE ratio is 60.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.62x versus 17.24x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Solventum Corp. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 60.4%. Boston Scientific Corp.'s return on equity of 12.46% beat Solventum Corp.'s return on equity of 42.2%.

Boston Scientific Corp. has a consensus price target of $118.78, signalling upside risk potential of 63.66%. On the other hand Solventum Corp. has an analysts' consensus of $89.25 which suggests that it could grow by 16.68%. Given that Boston Scientific Corp. has higher upside potential than Solventum Corp., analysts believe Boston Scientific Corp. is more attractive than Solventum Corp..

Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.

Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than Solventum Corp. quarterly revenues of $2.1B. Boston Scientific Corp.'s net income of $670M is lower than Solventum Corp.'s net income of $1.3B. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 38.94x while Solventum Corp.'s PE ratio is 8.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.62x versus 1.59x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 12.68% compared to Boston Scientific Corp.'s net margin of 17.41%. Boston Scientific Corp.'s return on equity of 12.46% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Boston Scientific Corp. has a consensus price target of $118.78, signalling upside risk potential of 63.66%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $340.71 which suggests that it could grow by 47.53%. Given that Boston Scientific Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Boston Scientific Corp. is more attractive than West Pharmaceutical Services, Inc..

Boston Scientific Corp. has a beta of 0.666, which suggesting that the stock is 33.441% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.063%.

Boston Scientific Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.37% to investors and pays a quarterly dividend of $0.22 per share. Boston Scientific Corp. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific Corp. quarterly revenues are $5.3B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Boston Scientific Corp.'s net income of $670M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Boston Scientific Corp.'s price-to-earnings ratio is 38.94x while West Pharmaceutical Services, Inc.'s PE ratio is 34.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific Corp. is 5.62x versus 5.58x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.